Filing Flows › Companies › Ultragenyx Pharmaceutical › Earnings quality
Ultragenyx Pharmaceutical earnings quality score
How much of the reported profit is backed by cash, and how many markers of managed earnings the filings show
Score67 / 100 · grade B · rank 485 of 1027
Ultragenyx Pharmaceutical (RARE) scores 67 of 100 for earnings quality, grade B: rank 485 of 1027 companies and 47 of 126 in health. It loses the most points on Montier C-score 3 of 5 checks failed, discretionary accruals of +5.4% of assets (modified Jones), larger than most, accruals of -7.2% of assets, lower than 73% of companies (profit backed by cash). It earns full or near-full marks for profit steadier than cash flow (smoothness 0.66), Dechow F-score 0.25 (normal).
What earned and lost points
| Component | What the filings show | Points | Of |
|---|---|---|---|
| Accruals | accruals of -7.2% of assets, lower than 73% of companies (profit backed by cash) | 20 | 27 |
| Dechow F-score | Dechow F-score 0.25 (normal) | 20 | 20 |
| Montier C-score | Montier C-score 3 of 5 checks failed | 8 | 20 |
| Discretionary accruals | discretionary accruals of +5.4% of assets (modified Jones), larger than most | 4 | 13 |
| Non-GAAP gap | adjusted earnings 9% below GAAP | 10 | 13 |
| Earnings smoothness | profit steadier than cash flow (smoothness 0.66) | 6 | 7 |
How the score is built
Eight published measures, each scored against the whole universe or on its own scale and weighted: accruals 20, discretionary accruals 10, Beneish M 15, Dechow F 15, Montier C 15, Piotroski F 10, the non-GAAP gap 10, smoothness 5. A measure that cannot be computed (Beneish for a bank, say) drops out and the rest is rescaled, so every company is scored on what applies to it.
Every company ranked → The full quality workbench, live → Ultragenyx Pharmaceutical: cash flow →
Computed from the companies’ own XBRL filings (latest fiscal year) by published formulas; a statistical screen, not an audit or an accusation. A low score means the reported profit shows more of the markers of managed or low-quality earnings than its peers. Not investment advice.